Literature DB >> 9433436

Overcoming the limitations of current meta-analysis of randomised controlled trials.

J Pogue1, S Yusuf.   

Abstract

For a meta-analysis to give definitive information, it should meet at least the minimum standards that would be expected of a well-designed, adequately powered, and carefully conducted randomised controlled trial. These minimum standards include both qualitative characteristics--a prospective protocol, comparable definitions of key outcomes, quality control of data, and inclusion of all patients from all trials in the final analysis--and quantitative standards--an assessment of whether the total sample is large enough to provide reliable results and the use of appropriate statistical monitoring guidelines to indicate when the results of the accumulating data of a meta-analysis are conclusive. We believe that rigorous meta-analyses undertaken according to these principles will lead to more reliable evidence about the efficacy and safety of interventions than either retrospective meta-analysis or individual trials.

Entities:  

Mesh:

Year:  1998        PMID: 9433436     DOI: 10.1016/S0140-6736(97)08461-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  88 in total

Review 1.  Randomised controlled trials in cardiovascular medicine: past achievements, future challenges.

Authors:  S Yusuf
Journal:  BMJ       Date:  1999-08-28

2.  Sample size estimation for the sorcerer's apprentice. Guide for the uninitiated and intimidated.

Authors:  J G Ray; M J Vermeulen
Journal:  Can Fam Physician       Date:  1999-07       Impact factor: 3.275

Review 3.  How strong is the evidence for the use of perioperative beta blockers in non-cardiac surgery? Systematic review and meta-analysis of randomised controlled trials.

Authors:  P J Devereaux; W Scott Beattie; Peter T-L Choi; Neal H Badner; Gordon H Guyatt; Juan C Villar; Claudio S Cinà; Kate Leslie; Michael J Jacka; Victor M Montori; Mohit Bhandari; Alvaro Avezum; Alexandre B Cavalcanti; Julian W Giles; Thomas Schricker; Homer Yang; Carl-Johan Jakobsen; Salim Yusuf
Journal:  BMJ       Date:  2005-07-04

4.  A meta-analysis of randomized controlled trials of intracoronary gamma- and beta-radiation therapy for in-stent restenosis.

Authors:  Takahiro Uchida; Ameet Bakhai; Alexandra Almonacid; Taro Shibata; Barbra Cox; Richard E Kuntz
Journal:  Heart Vessels       Date:  2006-11-27       Impact factor: 2.037

5.  Inhaled nitric oxide for acute respiratory distress syndrome.

Authors:  Niall D Ferguson
Journal:  BMJ       Date:  2007-04-14

6.  The grammar of interpretive medicine.

Authors:  R Horton
Journal:  CMAJ       Date:  1998-08-11       Impact factor: 8.262

Review 7.  Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis.

Authors:  Geert Koster; Jørn Wetterslev; Christian Gluud; Jan G Zijlstra; Thomas W L Scheeren; Iwan C C van der Horst; Frederik Keus
Journal:  Intensive Care Med       Date:  2014-12-18       Impact factor: 17.440

Review 8.  Avoidance versus use of neuromuscular blocking agents for improving conditions during tracheal intubation or direct laryngoscopy in adults and adolescents.

Authors:  Lars H Lundstrøm; Christophe Hv Duez; Anders K Nørskov; Charlotte V Rosenstock; Jakob L Thomsen; Ann Merete Møller; Søren Strande; Jørn Wetterslev
Journal:  Cochrane Database Syst Rev       Date:  2017-05-17

9.  Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals.

Authors:  Kristian Thorlund; Aranka Anema; Edward Mills
Journal:  Clin Epidemiol       Date:  2010-08-09       Impact factor: 4.790

10.  Estimating required information size by quantifying diversity in random-effects model meta-analyses.

Authors:  Jørn Wetterslev; Kristian Thorlund; Jesper Brok; Christian Gluud
Journal:  BMC Med Res Methodol       Date:  2009-12-30       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.